Lucas Wamser Fonseca Gonzaga

Mr. Lucas Wamser Fonseca Gonzaga

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
LGLucas Wamser Fonseca Gonzaga
Lucas Wamser Fonseca Gonzaga
BEBeatriz Monte Egito
Beatriz Monte Egito
JCJoão Bosco Costa Coelho
João Bosco Costa Coelho
GSGabriela Pereira Souza
Gabriela Pereira Souza
Frederico MartinsFrederico Martins
Frederico Martins
MFMARCOS FERRANTE
MARCOS FERRANTE
Background: A PBPK model allows the prediction of the concentration of drug amounts in different tissues and organs over time and can be used to simulate and optimize different therapeutic protocols in healthy and sick individuals. The objective of this work was to create a PBPK model to predict propofol doses for healthy canines and canines with hepatic impairment. Methods: The study methodology was divided into two major phases, in which the first phase consisted of creating the PBPK model for healthy canines, and in the second phase, this model was adjusted for canines with hepatic impairment. The model for healthy canines presented good predictive performance, evidenced by the value of the performance measure of the geometric mean fold error that ranged from 0.8 to 1.25, meeting the double error criterion. The simulated regimen for healthy canines, i.e., of 5 mg/kg (administered as a bolus) followed by a continuous infusion at a rate of 0.13 mg/kg/min, was sufficient and ensured that all simulated subjects achieved the target plasma concentration. Canines with 60% and 40% liver function had infusion rate adjustments to ensure that individuals did not exceed the therapeutic window for maintenance of anesthesia. Results: The results presented in this manuscript are suggestive of the effectiveness and practicality of a PBPK model for propofol in canines, with a particular focus on hepatic impairment.

1 January 2023 in Arquivo Brasileiro de Medicina Veterinária e Zootecnia
Verified
Journal Article
Open access
PDF file
LFLarissa Alexsandra Felix
Larissa Alexsandra Felix
LGLucas Wamser Fonseca Gonzaga
Lucas Wamser Fonseca Gonzaga
BSBruna Christina Fernandes Soares
Bruna Christina Fernandes Soares
GSGonzalo Suárez
Gonzalo Suárez
HBHumberto de Mello Brandão
Humberto de Mello Brandão
MFMARCOS FERRANTE
MARCOS FERRANTE
This study aims to determine therapeutic protocols of intramuscular sodium cloxacillin (IM) in goats with potential antibacterial effects against Staphylococcus spp. We constructed a pharmacokinetic (PK) model of IM, followed by a pharmacokinetic/pharmacodynamic integration (PK/PD). Simulations of different therapeutic protocols were then performed, with the doses ranging from 30 to100 mg/kg every 8, 12, or 24 hours. We calculated the probability to target attainment (PTA) of reach protocol's therapeutic according to the minimum inhibitory concentration (MIC) range of 0.06 to 4 μg/mL. The PK/PD index (PDT) used was "time above the MIC for 40% of the time" (T>MIC ≥40%). Protocols with single administration per day were incapable of achieving PTA ≥ 90% for any of the estimated MICs. However, by decreasing the administration interval, the PTA was increased. Thus, from the dose of 50 mg/kg every 12 hours, a PTA≥ 90% for MICs ≤ 0.5 μg/mL was achieved, while the 30 mg/kg dose every 8 hours was able to achieve a PTA≥ 90% for MICs of 2 μg/mL. The results suggest using 30 mg/kg dose every 8 hours in clinical studies of agents with MICs ≤ 2μg/mL; Nevertheless, the practitioner should adjust the dose in severe patients.

22 December 2022 in Revista de Investigaciones Veterinarias del Perú
Verified
Journal Article
Open access
PDF file
ETEmanuely Ramos Tameirão
Emanuely Ramos Tameirão
FRFernando Marcos Rubim
Fernando Marcos Rubim
LFLarissa Alexsandra Felix
Larissa Alexsandra Felix
LGLucas Wamser Fonseca Gonzaga
Lucas Wamser Fonseca Gonzaga
HBHumberto de Mello Brandão
Humberto de Mello Brandão
MFMARCOS FERRANTE
MARCOS FERRANTE
El objetivo de este trabajo fue desarrollar un modelo farmacocinético de florfenicol en plasma de tilapia (Oreochromis niloticus) sometido a diferentes temperaturas de crianza para estimar la concentración plasmática de los protocolos indicados en los prospectos de productos de florfenicol autorizados en Brasil. Para ello, se creó un modelo farmacocinético a partir de datos previamente publicados sobre la concentración plasmática de florfenicol en tilapia del Nilo sometida a diferentes temperaturas. La construcción del modelo farmacocinético se realizó con el programa Monolix 2020R1 de Lixoft®, partiendo de los datos de farmacocinética plasmática de florfenicol encontrados en la literatura. Las concentraciones plasmáticas de florfenicol se estimaron a partir de tratamientos con dosis de 10, 15 y 20 mg/kg administradas cada 24 horas durante 10 días, a temperaturas de 18, 21, 26 y 30°C, utilizando el programa Simulx 2020 de Lixoft®. Los parámetros de tiempo de latencia de absorción (Tlag) y aclaramiento (Cl) mostraron una correlación positiva con la temperatura, mientras que la constante de absorción (Ka) mostró una correlación negativa. Asimismo, se puede observar que los animales mantenidos a 30 ºC tienen una mediana de la concentración plasmática móvil de aproximadamente la mitad que los animales criados a 18 ºC y tratados con las mismas dosis. Por otra parte, las dosis crecientes determinaron un aumento de aproximadamente el doble de las medianas de la concentración plasmática. El modelo propuesto permitió cuantificar el impacto de la temperatura en los parámetros farmacocinéticos, además de estimar las concentraciones plasmáticas de florfenicol para tilapia a diferentes temperaturas de crianza.

1 January 2026 in Ciência Rural
Verified
Journal Article
Open access
GSGabriela Pereira Souza
Gabriela Pereira Souza
LGLucas Wamser Fonseca Gonzaga
Lucas Wamser Fonseca Gonzaga
PAPablo Henrique Silva Avelar
Pablo Henrique Silva Avelar
JCJelieny Aparecida Claudino
Jelieny Aparecida Claudino
MTMarilda Onghero Taffarel
Marilda Onghero Taffarel
MFMARCOS FERRANTE
MARCOS FERRANTE
The aim was to compare the administration of propofol via bolus or continuous infusion for anesthetic induction in dogs. Twenty-four healthy adult dogs were randomized into one of two groups: anesthetic induction with intravenous propofol as a 1 mg/kg bolus every 60 seconds (Group B) or continuous infusion at 1 mg/kg/min using a syringe pump (Group CI) following premedication with acepromazine (0.02 mg/kg) and methadone (0.3 mg/kg). The propofol dose, induction time, physiological variables, and the occurrence of myoclonus, hypotension, apnea, desaturation, and hypercapnia after anesthetic induction were evaluated. Independent numerical variables were compared using the Student’s t-test or Mann-Whitney test, while physiological variables were analyzed using repeated measures ANOVA or Friedman test, followed by post hoc comparisons. The significance level was set at P < 0.05. The propofol dose was lower in Group B than in Group CI (3 mg/kg [3 - 3.3] vs. 4.5 mg/kg [3.5 - 5.6], respectively, P = 0.002), and the induction time was shorter in Group B than in Group CI (3 min [3 - 3.25] vs. 4.5 min [3 - 6.25], respectively, P = 0.027) (median and interquartile range). There was no difference in adverse effects between the groups. It is concluded that administering propofol in a 1 mg/kg bolus every 60 seconds allows anesthetic induction with a lower dose and shorter time, with no difference in adverse effects compared to continuous infusion at 1 mg/kg/min.

28 February 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Kevellyn Silveira Gomes MartinsKevellyn Silveira Gomes Martins
Kevellyn Silveira Gomes Martins
LGLucas Wamser Fonseca Gonzaga
Lucas Wamser Fonseca Gonzaga
LFLarissa Alexsandra Felix
Larissa Alexsandra Felix
RMReiner Silveira de Moraes
Reiner Silveira de Moraes
PGPriscylla Tatiana Chalfun Guimaraes-Okamoto
Priscylla Tatiana Chalfun Guimaraes-Okamoto
MFMARCOS FERRANTE
MARCOS FERRANTE
Background/Objectives: The aim of the study was to develop a physiologically based pharmacokinetic (PBPK) model to predict gentamicin therapeutic protocols for dogs with varying degrees of renal function impairment, considering the minimum inhibitory concentrations (MICs) of the infecting bacteria. Methods: The PBPK model was built using PK-Sim® software (OPEN SYSTEMS PHARMACOLOGY), based on pharmacokinetic data available in the literature and information on the physicochemical properties of the drug. Model evaluation included the calculation of the geometric mean fold error (GMFE), weighted and percentage residuals were calculated, as well as the following measures: AFE, AWRi, MWRi, MAWRi, APE%, MPE%, MAPE%, MdPE%, and MdAPE%. Therapeutic efficacy was assessed according to the Probability of Target Attainment (PTA), considering an MIC distribution of 0.25 to 8 μg/mL for different doses (2, 4, 6, 8, and 10 mg/kg) using the PK/PD indices Cmax/MIC ≥ 10, AUC/MIC ≥ 50, and AUC/MIC ≥ 110. To compare the pharmacokinetics of gentamicin between healthy dogs and those with decreased renal function, different GFR values corresponding to stages of renal impairment were used, as determined by clinical biomarkers (microalbuminuria, UPC ≥ 2, sCr ≥ 1.2 mg/dL, sCr ≥ 2.4 mg/dL, and sCr ≥ 5 mg/dL). The risk of toxicity was assessed according to AUC24h ≥ 700 mg·h/L and Cmin ≥ 0.5. Results: The model demonstrated good predictive performance, with a GMFE value of 1.13 meeting the double error criterion, and weighted residuals randomly distributed around 0 (p = 0.3792). Through the calculation of PTA, it was observed that efficacy varied according to the PK/PD index used, but values greater than 90% were obtained for MICs up to 4 μg/mL. The model allowed the estimation of protocols for each stage of renal impairment, considering the GFR of each group and the risk of nephrotoxicity, in association with the optimal dose to ensure therapeutic efficacy. Conclusions: These findings make it possible to propose a dose for the treatment of an infection, considering the MIC and the patient’s GFR stage, thereby reducing the risk of adverse effects without compromising treatment efficacy.

1 September 2022 in Pubvet
Verified
Journal Article
Closed access
PDF file
HRHenrique Ribeiro Alves de Resende
Henrique Ribeiro Alves de Resende
JAJoão Vitor Fernandes Cotrim de Almeida
João Vitor Fernandes Cotrim de Almeida
JCJoão Bosco Costa Coelho
João Bosco Costa Coelho
LGLucas Wamser Fonseca Gonzaga
Lucas Wamser Fonseca Gonzaga
MFMARCOS FERRANTE
MARCOS FERRANTE
IPIrvênia Luiza de Santis Prada
Irvênia Luiza de Santis Prada
A glândula pineal (GP), integrante do epitálamo, mostra-se sensível à luz e, nos vertebrados, secreta melatonina, na ausência de luminosidade. Este hormônio parece interferir na adaptação das funções reprodutivas às condições de luminosidade, especialmente, em animais que se reproduzem sazonalmente como os equinos, possibilitando o parto em épocas de clima mais quente e favorável à disponibilidade de alimentos. Diante disso, objetivou-se avaliar e descrever os componentes ultraestruturais da GP de 24 éguas, distribuídas em duas fases: estação de monta e anestro fisiológico, cada uma com 2 grupos (3-8 e 15-20 anos). A GP foi retirada após o abate dos animais e processada em etapas de fixação, secções histológicas e colorações. A análise do material processado foi realizada utilizando-se microscopia de luz e de transmissão. Os dados foram submetidos à análise estatística. A GP foi encontrada no plano sagital mediano, dorsocaudalmente à aderência intertalâmica e ventralmente ao esplênio do corpo caloso, apresentando formato ovoide ou piriforme. Estava envolvida por cápsula de tecido conjuntivo, da qual partem septos que, acompanhados por vasos sanguíneos, dividem o parênquima em lóbulos. Os principais componentes glandulares foram pinealócitos e astrócitos. Concreções calcárias foram evidenciadas no núcleo e no citoplasma de pinealócitos, bem como no espaço extracelular de todas as GPs, independentemente da idade e/ou fase reprodutiva. Por outro lado, animais em anestro fisiológico apresentaram maior número de pinealócitos.